GlassScriptPhysician profile
Yenny S Lim
NPI 1598877557
$1,813.19
in general payments reported to CMS, 2019-2025
21 companies · $632 in 2025
The $632 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $445 · 2020: $21.81 · 2021: $19.12 · 2023: $232 · 2024: $463 · 2025: $632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,327.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $281.93 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $241.76 | 2019-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $238.24 | 2023-2025 | Wegovy |
| Pfizer INC. | $172.08 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $161.58 | 2019-2025 | Spravato |
| Novartis Pharmaceuticals Corporation | $161.00 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $112.08 | 2019 | |
| Abbvie INC. | $96.25 | 2023-2025 | |
| Astellas Pharma US INC | $74.26 | 2019-2025 | Veozah |
| Verity Pharmaceuticals INC. | $34.80 | 2025 | Tlando |
| Viiv Healthcare Company | $34.43 | 2025 | Apretude |
| Exact Sciences Corporation | $30.39 | 2023-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $28.13 | 2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $27.46 | 2024 | Breztri |
| Idorsia Pharmaceuticals US INC | $19.92 | 2023 | Quviviq |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $19.34 | 2024 | Voquezna |
| Antares Pharma, INC. | $17.75 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.13 | 2019 | |
| Phadia US INC. | $16.87 | 2024 | Immunocap |
| Intra-Sana Laboratories | $14.19 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Merck Sharp & Dohme LLC | $13.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yenny Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.